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Novel therapeutic agents discovery have become crucial because humankind is experiencing issues regarding
health and the environment. The present study is focusing on thrombolytic agents, which are therapeutics for
cardiovascular diseases, eco-friendly, safe and can be used in comparison to synthetic agents that are associated
with some side effects and their production is not environment friendly. The main objective of the present
research was to evaluate the thrombolytic and cytotoxic potential of different extracts of Escherchia coli-
ATCC35218. Soxhlet extraction method with ethanol was used for extraction from cells. Crude protein was
extracted from the cell mass with protein extraction buffer. Crude isoprenoid quinone and polar lipids were
extracted by using petroleum ether with methanol and chloroform as extraction solvent. In another method, the
extracts were prepared using methanol as well as n-hexane, chloroform, ethyl acetate and water in serial
extraction. These organic and aqueous extracts of E. coli were dried, weighed, dissolved in DMSO and tested for
their hemolytic and thrombolytic potential. Mild to moderate percentage of thrombolytic activity was shown by
these extracts and compared with citric acid (standard). Chloroform, ethyl acetate and methanol soluble extracts
showed significant thrombolytic activities that were 43.5%  0.06, 41.8%  0.16 and 40.5%  0.07 respectively,
while citric acid showed 73.7%  0.05. Maximum hemolytic activities were shown by polar lipids, crude
methanol extract and n-hexane that are 87.20%  0.08, 82.5%  0.06 and 73.46% 0.08 respectively as
compared with 0.1% Triton X-100 (positive control) with 94.75%  0.15 hemolysis. Finally, results were
analyzed statistically through analysis of variance (ANOVA). Further studies on isolation and identification of
bioactive thrombolytic agents from each bioactive thrombolytic extract will help us in reporting natural throm-
bolytic agents from E.coli that could benefit human medically. This is one of the few reports of thrombolytics
available from natural sources.1. Introduction
Since decades, environmental and health problems are the main
challenges for men. As pathogens have developed resistance against a
number of antibiotics therefore, treatment of infections caused by them is
a great challenge [1]. A variety of problems regarding health causes due
to the toxins in the food and due to thrombolytic disorders e.g., intra-
vascular thrombosis, myocardial infarction and acute ischemic strokes.
From the World Health Organization (WHO) records these thrombolytic
disorders causes the death of about 117 people [2,3]. Different toxins
naturally present in foods such as aflatoxin M1 (AFM1) and Aflatoxin B1(Z. Mushtaq), Farooq.Sher@coven
orm 6 January 2021; Accepted 9
vier Ltd. This is an open access ar(AFB1) can cause risks to human health regarding the impairment of
them in the intestine [4]. Clostridium perfringens produce four major
toxins that causes different types of food poisoning issues that may be
fetal [5].
Therefore, there is a need for new therapeutic agents due to these
health and environmental issues. To overcome these hazardous chal-
lenges, new therapeutic technologies for the discovery of novel thera-
peutics is the main focus of scientists [6]. Compounds that have
interaction with living cells and imposes important health effects are the
bioactive compounds. These bioactive compounds with important health
effects such as least cytotoxicity and thrombolytic effect are produced bytry.ac.uk, Farooq.Sher@gmail.com (F. Sher).
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metabolites like alkaloids, terpenoids, isoprenoids and proteins like
defensins which possess hemolytic and thrombolytic potential [8]. These
bioactive compounds have broad range applications in industries and
medicine [6].
Variety of enzymes with thrombolytic potential have been identified
in different microorganisms like staphylokinase produced by Strepto-
coccus aureus and Streptokinase produced by Streptococcus hemolyticus
with significant thrombolytic potential. Nattokinase produced by Bacillus
subtilis [2]. These enzymes from various biological sources usually acted
by catalyzing or activating the plasminogen to plasmin which in response
catalysis the degradation of thrombus or fibrin clots whereas sometimes
they directly degrade the clot [9]. Escherichia coli was first demonstrated
for the presence MEP (methyl-D-erythritol-4-phosphate) pathway which
is involved in plastidic isoprenoids biosynthesis [10]. These isoprenoids
are reported for their thrombolytic potential [11]. The E. coli strain is also
studied for the production of recombinant streptokinase which later on
used for the thrombolytic analysis and found active [12].
From the literature survey, E. coli is not much studied for its throm-
bolytic potential [13]. Kiwi-fruits ethanol fractions are ascorbic acid,
flavonoids (Quercetin) and phenols rich that possess considerable
bioactive potentials like cytotoxicity and antioxidant activities [14].
E.coli can play a positive role in the development of novel thrombolytic
therapeutic agents and could be of good scope to study this strain in more
detail [12]. Moreover, natural products are much more eco-friendly to be
synthesized as compared to the synthetic therapeutics with least side
effects too. Ethanol extract of the microalgae like Synechocystis sp. and
algae Himanthalia elongate possess compounds with bioactive potential
like palmitoleic acid, palmitic or neophytadiene, fucosterol, oleic acids
and phytol were screened. These extracts exhibit antimicrobial and
antioxidant activities [15]. Chloroform, methanol, chloroform: alcohol
(1:1), ethyl acetate and hexane fractions of different algae contain pig-
ments like chlorophylls, vitamin C and amino acids with cytotoxic,
antimicrobial and antioxidant activities [16]. Bioactive compounds of
ethyl acetate fractions of C. humicola are saponins, alkaloids, fatty acids,
flavanoids and amino acids with antimicrobial potential [17].
There is a need for novel bioactive agents and other techniques for
screening of these compounds from microorganisms (i.e. natural sour-
ces). Therefore, the present research work is conducted for the evaluation
of more bioactive compounds from E. coli to address the thrombolytic and
cytotoxic potential of each extract. The main purpose of the study is to
explore novel bioactive compounds from microbial resources of E.coli
ATCC35218 for therapeutic and cytotoxic potentials. Furthermore, the
research is quite worthy in environmental perspectives and could be
considered an eco-friendly therapeutic approach of discovery.Fig. 1. Overview of working strategy adopted for using E.Coli extrac
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2. Material and methods
2.1. Culturing and cell harvesting of bacterial strain
E. coli (ATCC 35218) strain was used in our study. The strain of
Escherichia coli specie was confirmed from the Institute of Microbiology,
University of Agriculture Faisalabad, Pakistan. Nutrient agar (NA) and
nutrient broth (NB) prepared by MERCK Company was used as a basal
medium to grow bacterial cultures [18]. Then the broth culture was
centrifuged at 10,000 rpm for 10 min at 4 C to obtain bacterial cell mass
that was dried, weighed and used for the extraction procedure. Fig. 1
represents the methodology and main findings of current research.
2.2. Extraction and fractionation
2.2.1. Protein extraction (PE)
Bacterial protein was extracted by following the procedure described
by Ref. [19], with little modifications. 1 g of dry cell mass of organism
was resuspended and sonicated for 10 min in 5 mL of protein extraction
buffer (10 mM Na2HPO4, 15 mM NaH2PO4, 100 mM KCl, 2 mM EDTA,
1.5% polyvinylpoly pyrrolidone (PVPP), 1 mM phenyl methyl sulfonyl-
floride (PMSF) and 2 mM thiourea) [20]. This mixture was then centri-
fuged at 10,000 rpm for 10 min stored at 4 C and filtered. The crude
protein contents of the sample were determined spectrophotometrically
by the Bradford method [21], using bovine serum albumin (BSA) as
standard.
2.2.2. Extraction through different organic and aqueous solvents
Method for solvent extraction was described by Emran and his co-
workers [22]. 5 g dry cell mass of E. coli was used for extraction.
Extraction was done by resuspending the dry cell mass in methanol fol-
lowed by stirring for 48 h and centrifuged to separate the cellular debris.
Then this crude methanol extract (CM) was subjected to fractionation
with different aqueous and organic solvents [water, n-hexane (NH),
chloroform (CL), ethyl acetate (EA) and methanol (ME) respectively].
Depending upon polarity of respective solvent different layers were
formed each time and carefully separated. These layers were then dried,
weighed, dissolved in DMSO (Dimethyl sulfoxide) and stored for further
bioactivity based studies.
2.2.3. Soxhlet extraction (SE)
The Soxhlet extraction (SE) was implementedwith 5 g of dry cell mass
of E. coli, a solvent was used for extraction was ethanol (b.p. 78.37 C).
12 h of extraction process at 100 C, followed by solvent evaporation.
The extract was dried, weighed, dissolved in Dimethyl sulfoxide (DMSO)
and used to evaluate their bioactive potential [23].ts as thrombolytics and significant findings of the present study.
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Mixtures containing chloroform and methanol have been shown to
provide efficient extraction of isoprenoid quinine (IQ) and polar lipids
(PL), and the established procedure of Bligh and Dyer has been conve-
niently used for the extraction of bacterial lipids [24].Fig. 2. Percentage thrombolytic activity of crude aqueous and organic extracts
of E. coli. The thrombolytic activity of E. coli extracts with different concentra-2.3. Thrombolytic activity
Experiments for clot lysis were carried out using standard procedure
reported earlier [25]. Each pre weighed tube containing clot was prop-
erly labelled and 100 μL of E. coli extracts were added to the tubes. As a
positive control, 100 μL of citric acid and as a negative control, 100 μL of
distilled water were separately added. All the tubes were then incubated
overnight (O/N) at 37 C and observed for clot lysis. The clot lysis cal-
culations were performed using Eq. (1).
Clot lysis ð%Þ¼ Wt: of released clot after drug
Sample application  Clot weight  100 (1)
where clot weight ¼ weight of clot containing tube – weight of an empty
tube.tions were evaluated. Citric acid was used as a control for thrombolytic agent in
this experiment. Each bar shows the data from three experiments with error bar
representing standard deviations on each. Chloroform (CL), ethyl acetate (EA),
and methanol soluble (MS), fractions showed maximum thrombolytic activity.
Other extracts also showed significant thrombolytic activity.2.4. Cytotoxicity studies by hemolytic activity
The cytotoxic studies of the E. coli extracts were analyzed by hemo-
lytic activity [26], 3 mL of freshly obtained blood was added in hepa-
rinized tubes to avoid coagulation and gently mixed, poured into a sterile
15 mL falcon tube and centrifuged for 5 min at 850 x g. RBCs were
washed three times with 5 mL of chilled (4 C) sterile isotonic phosphate
buffer saline (PBS) solution, pH 7.4. The washed RBCs were counted on
hemocytometer. The RBCs count was maintained to 7.068 x 108 cells per
mL for each assay. The 20 μL of E. coli extracts were taken in 2 mL
microcentrifuge tube then added 180 μL diluted blood cell suspension.
The samples were incubated for 35 min at 37 C and then centrifuged for
5 min at 1310 x g. After centrifugation 100 μL supernatant was taken
from the tubes and diluted with 900 μL ice-cold PBS. After this 200 μL
mixture from each microcentrifuge tube was added into 96 well plates.
For each assay, 0.1% triton X-100 was taken as a positive control for
100% lysis and phosphate buffer saline (PBS) was taken for each assay as
a negative control. The absorbance was noted at 576 nmwith a Bio TeK, μ
Quant (BioTek, Winooski, VT, USA) [26]. The experiment was performed
in triplicate and average results were calculated. The percentage He-
molysis was calculated using Eq. (2).Lysis of RBCs ð%Þ¼Absorbance of sample –Absorbance of Negative control
Absorbance of positive control
 100 (2)2.5. Statistical analysis
Results were analyzed statistically in which the significance of mean
zone of inhibition between standards and E. coli extracts were tested by
the paired t-test (Tucky’s test) analysis using software Statistix, version
8.1. Data were expressed as mean  S.E.
3. Results and discussion
3.1. Extraction of bioactive fractions from E. coli
An integrated procedure was used [24] for the extraction of iso-
prenoid quinines (IQ) and polar lipids (PL) in which 500 mg of dry cell
mass of E. coliwas used. Crude IQ and PL yields were 20 and 26.6 mg/mL3
of DMSO respectively. Isoprenoid quinines (IQ) are derivative of quinine
and active biological motif. The extraction of quinone an organic motif
from different bacterial strains have been reported well in literature [27,
28]. The bacterial strains which were used for the extraction of quinine
are AS-S20-I [28] and Bacillus clausii [27]. One of these strains has
shown fibrinolytic activity, while both (AS-S20-I and Bacillus clausii) of
these exhibited a great potential of the thrombolytic activity. Whereas
different E.coli strains have also been used for the extraction of lipid
molecules active against the thrombosis a severe medical condition. In
addition to thrombolytic activity hemolytic potentials are also reported
[29]. In literature, a detergent octyl-β-D-glucopyranoside is considered as
a lipid forming chemical which showed the above-mentioned activities
[29].
In previous research work, the strain (ATCC 35218) was also used for
the evaluation of antimicrobial and antioxidant potentials and foundgood results [30]. However, in the current study, the strain (ATCC
35218) of E. coli was employed for the extraction of polar lipids and
showed high thrombolytic and cytotoxic activities, proved by our
experimental work. Soxhlet extraction (SE) was performed by using 5 g of
dry cell mass of E. coli and its ethanol extractable yield was 150mg/mL of
dimethyl sulfoxide (DMSO). For solvent-based extraction a method re-
ported earlier [22] was followed. E. coli dry cell mass of 5 g was subjected
to extraction by using different aqueous and organic solvents by
following the method already reported [22]. By which extracts abbre-
viated as CM, NH, CL, EA, MS andWSwith yields of 125, 61, 60, 100, 146
and 50 mg/mL of dimethyl sulfoxide respectively were obtained. Crude
protein contents were also extracted by following reported procedure
[19], using 1 g dry E. coli cell mass and 5 mL protein extraction buffer
[20] and its yield was 163 μg/mL.
Table 1





CM 30.8E  0.08 82.57C  0.06
NH 16.4I  0.10 73.46D  0.08
CL 43.5B  0.06 46.47E  0.09
EA 41.8C  0.16 33.72F  0.12
MS 40.5C  0.07 3.2K  0.17
WS 26.4G  0.15 6.65J  0.21
CP 36.7D 0.09 23.52G ± 0.13
IQ 28.5F  0.05 20.46H  0.17
PL 36.5D  0.05 87.20B  0.08
EE 24H  0.09 18.63I  0.13
Citric acid (þve control) 73.7A  0.05 –
dH2O (-ve control) 4.9J  0.12 –
Triton-X100 (þve control) – 94.75A ± 0.15
PBS (-ve control) – 0.57L  0.015
The values are mean  S.E (standard error) of three replicate experiment.
*Means sharing same alphabets are statistically non-significant (P > 0.05).
Fig. 3. Hemolytic activity of E. coli extracts. Hemolytic activity of E. coli extracts
with respect to 0.1% Triton X-100 (positive control) presented as Triton in
graph. Each bar showing the data from three experiments with error bar rep-
resenting standard deviations. Polar lipid extract showed maximum hemolytic
activity and methanol soluble fraction showed minimum activity when
compared with Trion-X100.
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The main objective of this thrombolytic assay evaluated the ability of
extracts to disrupt already formed blood clot that may cause serious
consequences like acute arterial thrombosis, pulmonary embolism,
myocardial infarction and ischemic strokes etc. [31]. Fig. 2 represents
percentage thrombolytic activity of crude aqueous and organic extracts of
E. coli. All the extracts showed considerable clot lysis activity (Table 1).
Citric acid and distilledwaterwere taken as positive and negative controls
that showed 73.7%  0.05 and 4.9%  0.12 clot lysis respectively.
Reduction in clot weight is expressed as its percentage of thrombolytic
activity. CL showed maximum (43.5%  0.06) clot lysis activity. This
maximumclot lysis activitywas due to the presence of lipids inCL [24,32].
EAandMSshowed41.8%0.16and40.5%0.07activities respectively.
This activity that was due to the EA extracts possess molecules like car-
bohydrates, fatty acids, aminoacids andMSextracts suchas phospholipids
[17,24]. Maximal clot lysis activity was shown by these extracts. On the
other hand, minimal clot lysis activity was shown by NH (16%).
Other extract’s clot lysis activities are documented in Table 1. In a
study held by Nighat et al. [27], the thrombolytic potential of Trevesia
palmate methanolic fractions (EA, MS, NH, CL and WS) were evaluated.
Results showed that CL showed maximum clot lysis activity (44.5%) as
compared to all others like MS (43%), NH (44.21%), CL (43.2%) and AQ
(40.3%) clot lysis activity. Results of these percentage clot lysis activity
were quite similar to our data except WS (Fig. 2). Reason for this dif-
ference in-activity is the extraction from two different sources as activity
varies from source to source. Our MS extract showed significant throm-
bolytic activity (40.5%  0.07) when compared with citric acid as a
positive control. In another study [33], MS extract of Commelina ben-
ghalensis showed significant thrombolytic activity (40.94%) when
compared with streptokinase (75%) as a positive control. These values
are in good agreement with the present results (Table 1).3.3. Hemolytic activity of E. coli extracts
E. coli extract’s cytotoxicity was evaluated by the hemolytic assay as
described by Powell et al. [26]. Hemolysis is the healthy red blood cells
rupturing that is the indication of cytotoxicity to RBC’s cells [34]. Fig. 3
represents percentage Hemolytic activity of E. coli extracts. The results
showed that PL and CM extracts/samples showed maximum hemolytic
activity that is 87.20%  1.25 and 82.57%  0.94 respectively. The ac-
tivity of CM may be due to the presence of phospholipids in it [24].
Results are compared with 0.1% Triton X-100 (positive control) with
94.75%  1.22 hemolytic activity. In a study held by Warawa et al. [35],
in which the hemolytic activity of proteins (EspA, EspB, and EspD) of
Entero-pathogenic E. coli (EPEC) was evaluated. These three proteins4
were found to possess significant hemolytic activity. Present study of
E. coli (ATCC 35218) crude protein extract also showed some hemolytic
activity (23.527%) (Table 1).
The detailed description of the methodology adopted and its output in
terms of positive and negative results from the E. coli strain ATCC35218
are presented in Fig. 1. The present work used E.coli strain (ATCC 35218)
for the extraction of thrombolytic compounds such as Isoprenoid
quinone, polar lipids and crude bioactive proteins, polar and nonpolar
active compounds. For obtaining polar and non-polar crude compounds
different organic solvents are used (Fig. 1). All these samples showed
thrombolytic and cytotoxic properties. However, these extracts or sam-
ples possessed positive (WS and MS extracts and residues are most safe
thrombolytics) and negative results (CL, EA, PL, CM and NH are also
thrombolytic but not safe i.e. highly toxic to cell).3.4. Environmental issues and health benefits of E. coli
E.coli is a Gram-negative bacterium from the family Enterobacteri-
aceae. According to the World Health Organization (WHO), the bacte-
rium is causing food borne diseases and can transmit in humans and
animals as well. However, it is just one side of the picture, there is a
bright side of this bacterium; it has potential thrombolytic activity as well
as antimicrobial and antioxidant activities [30]. Therefore, this study is
of good scientific worth as it is designed to minimize potential environ-
mental and health concerns. It could also be described as an approach to
introduce E. coli as an eco-friendly source of therapeutic agents with
different safety levels that are still needed to be explored.
4. Conclusions
Based on the present study, it is suggested that E. coli extracts like
chloroform, ethyl acetate, methanol soluble fraction or residue and crude
methanol extract, n-hexane, polar lipids can be used against thrombolytic
and hemolytic disorders respectively. Still, there is a need for extensive
studies in order to explore the agents present in each sample that could be
an important way to report safe thrombolytic molecules for drug
designing. In vivo studies could be helpful in determining the real po-
tential usefulness of these E. coli samples for the treatment of hemolytic
and thrombolytic disorders.
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